Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Profit After Tax (2016 - 2025)

vTv Therapeutics' Profit After Tax history spans 12 years, with the latest figure at -$7.1 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 401.62% year-over-year to -$7.1 million; the TTM value through Dec 2025 reached -$31.1 million, down 68.35%, while the annual FY2025 figure was -$31.1 million, 68.35% down from the prior year.
  • Profit After Tax for Q4 2025 was -$7.1 million at vTv Therapeutics, up from -$10.3 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $614000.0 in Q3 2021 and bottomed at -$10.3 million in Q3 2025.
  • The 5-year median for Profit After Tax is -$5.8 million (2023), against an average of -$5.1 million.
  • The largest annual shift saw Profit After Tax skyrocketed 140.05% in 2021 before it crashed 990.55% in 2022.
  • A 5-year view of Profit After Tax shows it stood at -$7.1 million in 2021, then skyrocketed by 97.43% to -$181000.0 in 2022, then plummeted by 75.14% to -$317000.0 in 2023, then tumbled by 348.9% to -$1.4 million in 2024, then crashed by 401.62% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Profit After Tax are -$7.1 million (Q4 2025), -$10.3 million (Q3 2025), and -$8.5 million (Q2 2025).